Koppers vs Ingevity
KOP and NGVT side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KOP and NGVT compare
Ingevity is the larger company, worth 3.7 times as much as Koppers ($2.0B against $555M).
Ingevity grew revenue faster over the last twelve months (−1.4% versus −5.0% for Koppers).
Ingevity keeps more of each dollar of sales as profit, with a net margin of 4.7% compared with −4.6% at Koppers.
Koppers pays a dividend yielding 1.2%; Ingevity does not pay one.
Koppers scores higher on the StockData Score (9 against 6 for Ingevity), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KOP | NGVT |
|---|---|---|
| Size and price | ||
| Market cap | $555M | $2.0B |
| Share price | $29.36 | $59.28 |
| Change, 1 year | 1.5% | 20.1% |
| Change, 5 years | −6.9% | −20.2% |
| Beta (5Y) | 0.92 | 0.76 |
| Employees | 971 | 1,500 |
| StockData Score | ||
| Total score | 9 (better) | 6 |
| Valuation score | 3 (better) | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 0 | 3 (better) |
| Health score | 2 (better) | 1 |
| Dividend score | 3 (better) | 0 |
| Valuation | ||
| P/E | – | 40.3× |
| P/S | 0.3× (better) | 1.8× |
| P/B | 1.4× (better) | 43.5× |
| EV/EBITDA | 43.3× | 22.7× (better) |
| P/FCF | 4.0× (better) | 13.2× |
| FCF yield | 25.0% (better) | 7.6% |
| Fair value | $57.26 | $33.70 |
| Margin of safety | 48.7% (better) | −75.9% |
| Growth | ||
| Revenue growth (TTM) | −5.0% | −1.4% (better) |
| Revenue growth, 5Y average | 2.4% (better) | −0.81% |
| Net income growth (TTM) | −675% | – |
| EPS growth (TTM) | −748% | – |
| EPS growth, 5Y average | −13.7% | – |
| Profitability | ||
| Gross margin | 22.4% | 41.1% (better) |
| Operating margin | −2.2% | – |
| Net margin | −4.6% | 4.7% (better) |
| FCF margin | 7.3% | 13.4% (better) |
| Return on equity | −19.0% | 64.4% (better) |
| Return on invested capital | −2.5% | – |
| Financial health | ||
| Debt / equity | 2.32 (better) | 25.59 |
| Net debt / EBITDA | 26.29 | 7.97 (better) |
| Interest coverage | −0.7× | – |
| Current ratio | 2.33 (better) | 1.61 |
| Altman Z-score | 1.86 | 2.19 (better) |
| Piotroski F-score | 8 (better) | 6 |
| Dividends and buybacks | ||
| Dividend yield | 1.2% | – |
| Years of dividend growth | 3 | – |
| Buyback yield | 9.3% (better) | 7.0% |
| Shareholder yield | 10.5% (better) | 7.0% |
| Ownership | ||
| Held by institutions | 103% | 102% |
| Held by insiders | 11.2% | 1.4% |
| Insider net buying, 12 months | −$5.6M | −$1.8M (better) |
| Short interest, % of float | 4.3% | 3.7% |
Go deeper
- KOP stock overview
- KOP income statement
- KOP valuation and score
- NGVT stock overview
- NGVT income statement
- NGVT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.